ClinicalTrials.gg
Not yet recruitingNCT07817017MedDiet in GDMUpdated Sep 16, 2026

Effect of an Early and Intensified Nutritional Intervention on the Risk of Developing Gestational Diabetes Mellitus

An interventional study of Nutritional intervention based on a Mediterranean diet in Gestational Diabetes Mellitus (GDM), Pregnancy and Mediterranean Diet, sponsored by Hospital San Carlos, Madrid. Not yet recruiting at 1 site in Spain. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Hospital San Carlos, Madrid · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if a nutritional intervention based on a Mediterranean diet (MedDiet), initiated early in pregnancy, reduces the incidence of gestational diabetes mellitus (GDM) and other adverse maternal, fetal and obstetric events in pregnant women considered high-risk. It will also learn about the stratification of GDM risk based on clinical, anthropometric, analytical and genetic characteristics.

The main questions it aims to answer are:

  • Does the nutritional intervention based on MedDiet reduce the incidence of GDM in women with high risk?
  • How can we stratify the risk of GDM? Researchers will compare an advanced nutritional intervention based on a Mediterranean diet to standard care (general recommendations given at the beginning of pregnancy).

Participants will:

  • Receive intensive nutritional counselling or standard regular recommendations during the first trimester of pregnancy.
  • Visit the clinic at the time of the first ultrasound (gestational week 8-11) and at the time of screening for GDM (gestational week 24-26).
  • Undergo a genetic test performed with a buccal swab.
02

Conditions studied

  • Gestational Diabetes Mellitus (GDM)
  • Pregnancy
  • Mediterranean Diet

Browse trials for

Keywords

  • gestational diabetes mellitus
  • pregnancy
  • mediterranean diet
  • poligenic risk score
  • genetic polymorphism
03

In context

Diabetes, Gestational

877 studies on the registry are indexed under Diabetes, Gestational; 203 are open to participants now.

This study's planned enrollment of 1,200 is above the median of 110 across 564 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Hospital San Carlos, Madrid is the lead sponsor of 74 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unassisted single pregnancy;
  • Age between 18 and 50 years old;
  • Fasting blood glucose \<92 mg/dl in the first gestational blood test;
  • First trimester ultrasound before the 12th gestational week.

Exclusion criteria

Exclusion Criteria:

  • Multiple or assisted pregnancies;
  • Any pregestational illness or pregestational treatment that may affect pregnancy;
  • Known intolerance/allergy to any component of the nutritional intervention.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,200 participants (estimated)

Study arms

  • No intervention
    Standard treatment

    The nutritional intervention will consist of providing information on healthy lifestyle measures through an 8-minute informational video (accessible via QR code at the consultation room or the permanent link https://www.youtube.com/watch?v=Qgcz5t9B9WI). Routine obstetric follow-up does not involve subsequent monitoring of adherence to these recommendations, beyond the usual follow-up.

  • Experimental
    Advanced treatment

    A specific nutritional intervention consisting of a group session that will last approximately one hour, led by a nutritionist from the research team. This session will explain in detail the key aspects of the MedDiet: consumption of \>40 ml/day of extra virgin olive oil, 30 g of nuts per day, 3-4 pieces of whole fruit (not juice), homemade stir-fries, 2-3 servings of vegetables and/or salads per day, 2-3 servings per day of low-fat dairy products, whole grains, 2-3 servings of legumes per week, consumption of fish, limiting the consumption of red meat, and avoiding ultra-processed products, sliced bread, soft drinks, juices, fast food, and pre-cooked products. Two telephonic interviews will be scheduled for follow-up around gestational weeks 16 and 20 to provide motivation and assess and reinforce adherence to these recommendations.

    Other: Nutritional intervention based on a Mediterranean diet

Interventions

  • OtherNutritional intervention based on a Mediterranean diet

    The nutritional intervention consists of a 1-hour group session led by a nutritionist from the research team. Includes a detailed description of the key aspects of the MedDiet: consumption of \>40 ml/day of extra virgin olive oil, 30 g of nuts per day, 3-4 pieces of whole fruit (not juice), homemade stir-fries, 2-3 servings of vegetables and/or salads per day, 2-3 servings per day of low-fat dairy products, whole grains, 2-3 servings of legumes per week, consumption of fish, limiting the consumption of red meat, and avoiding ultra-processed products, sliced bread, soft drinks, juices, fast food, and pre-cooked products. In addition, 2 telephonic interviews for follow-up (gestational weeks 16 and 20) to reinforce adherence and emphasize consumption of \>40 ml/day of extra virgin olive oil, 30 g of nuts per day, 3-4 pieces of whole fruit (not juice), daily vegetables and daily physical activity.

06

What researchers measure

Primary outcomes

  1. Incidence of gestational diabetes mellitus

    The general objective of this study is to determine whether an advanced nutritional intervention based on Mediterranean diet reduces the incidence of gestational diabetes mellitus and other adverse maternal-fetal obstetric and endocrine-metabolic events in pregnant women considered high-risk based on a risk score derived from the interaction between associated genetic polymorphisms, baseline clinical characteristics, and anthropometric characteristics of pregnant women. The primary outcome is the comparison of the frequency of GDM, according to IADPSG criteria, between the MedDiet intervention group and the standard treatment group in women at high risk according to the calculated risk of developing GDM.

    Time frame: From enrollment (gestational week 8-11) to the time of screening for gestational diabetes mellitus (gestational week 24-26)

Secondary outcomes

  1. Frequency of maternal complications

    Frequency of maternal complications between the MedDiet intervention group and the standard treatment group in women at high risk according to the calculated risk of developing GDM. Variables for this outcome include: maternal weight, weight gain; risk score; frequency of maternal complications (hypertension, eclampsia, infections, carbohydrate metabolism disorders - defined as alterations in normal levels of at least one of the following: fasting glucose, HbA1c, C-peptide, insulin, HOMA-IR)

    Time frame: From enrollment (gestational week 8-11) to delivery

  2. Frequency of fetal complications

    Comparison of the frequency of fetal complications between the MedDiet intervention group and the standard treatment group in high-risk women, based on the calculated risk of developing gestational diabetes mellitus (GDM). Variables for this outcome include: birth weight, hypoglycemia, potassium abnormalities, calcium abnormalities, polycythemia, admission to the neonatal intensive care unit (NICU).

    Time frame: From enrollment (gestational week 8-11) to delivery and neonatal period

  3. Frequency of obstetric complications

    Comparison of the frequency of obstetric complications between the MedDiet intervention group and the standard treatment group in women at high risk of developing GDM. Variables for this outcome include: type of delivery, dystocia, lacerations during delivery, preterm or postterm delivery (gestational week at delivery).

    Time frame: From enrollment (gestational week 8-11) to delivery and immediate postpartum

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The original protocols of the study will be stored in a locked office in the Department of Endocrinology at our Hospital. De-identified data will be saved on a secure electronic database. Specifically, we will use REDCap® (Vanderbilt University) software, which is known to be a secure, browser-based web application (http://project-redcap.org), for data entry and analysis. All participant data related to the study, including scales and questionnaires, will be completed in paper form, and will then be recorded and uploaded in the REDCap®Electronic Data Collection Record (eCRD).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07817017
Lead sponsor
Hospital San Carlos, Madrid
Responsible party
Ana M. Ramos-Leví (Principal Investigator. M.D., PhD., Hospital San Carlos, Madrid) — Principal investigator
First posted
Sep 14, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 16, 2026

Study contacts

Ana M. Ramos-Levi, MD., PhD.
Contact
ana_ramoslevi@hotmail.com
+33696938427

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion